Niall O'Donnell

About

Niall O’Donnell joined RiverVest® in 2006 as a Kauffman Fellow and became a managing director in 2014. He focuses on biopharmaceutical, diagnostic and medical device opportunities and contributes to the formation, development and business strategies of RiverVest portfolio companies. Dr. O’Donnell is a board member of Amplyx Pharmaceuticals, Lyric Pharmaceuticals and co-founder of Reneo Pharmaceuticals. Dr. O’Donnell was acting interim chief medical officer at Lumena Pharmaceuticals, Inc. where he was central to the development and execution of its clinical strategy prior to the company’s acquisition by Shire plc in 2014. He also served on the board of Excaliard Pharmaceuticals, Inc., which was acquired by Pfizer Inc. Dr. O’Donnell helped co-found and seed Excaliard, develop the company’s clinical strategy and is a co-inventor on several key Excaliard patents. He was an observer at Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma, and at Otonomy, Inc., which completed

Investment Focus

Location

Encinitas, US